Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Sichuan Baili Pharmaceutical Co., Ltd.
University of Pittsburgh
M.D. Anderson Cancer Center
Hummingbird Bioscience
Bristol-Myers Squibb
National Cancer Institute (NCI)
NRG Oncology
Amgen
Memorial Sloan Kettering Cancer Center
National Institutes of Health Clinical Center (CC)
Dana-Farber Cancer Institute
Gustave Roussy, Cancer Campus, Grand Paris